201 related articles for article (PubMed ID: 22493415)
1. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation.
Hoskins PJ; Le N; Gilks B; Tinker A; Santos J; Wong F; Swenerton KD
J Clin Oncol; 2012 May; 30(14):1656-62. PubMed ID: 22493415
[TBL] [Abstract][Full Text] [Related]
2. Survival impact of capsule rupture in stage I clear cell carcinoma of the ovary in comparison with other histological types.
Higashi M; Kajiyama H; Shibata K; Mizuno M; Mizuno K; Hosono S; Kawai M; Nakanishi T; Nagasaka T; Kikkawa F
Gynecol Oncol; 2011 Dec; 123(3):474-8. PubMed ID: 21955484
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
[TBL] [Abstract][Full Text] [Related]
4. Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas.
Kumar A; Le N; Gilks CB; Santos JL; Wong F; Swenerton K; Hoskins PJ; McAlpine JN; Tinker AV
Int J Gynecol Cancer; 2017 Nov; 27(9):1819-1825. PubMed ID: 28930809
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant chemotherapy for stage i ovarian clear cell carcinoma: is it necessary for stage IA?
Mizuno M; Kajiyama H; Shibata K; Mizuno K; Yamamuro O; Kawai M; Nakanishi T; Nagasaka T; Kikkawa F
Int J Gynecol Cancer; 2012 Sep; 22(7):1143-9. PubMed ID: 22801028
[TBL] [Abstract][Full Text] [Related]
6. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
7. Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.
Shu CA; Zhou Q; Jotwani AR; Iasonos A; Leitao MM; Konner JA; Aghajanian CA
Gynecol Oncol; 2015 Nov; 139(2):236-41. PubMed ID: 26404183
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: an analysis of fully staged patients.
Takada T; Iwase H; Iitsuka C; Nomura H; Sakamoto K; Omatsu K; Takeshima N; Takizawa K
Int J Gynecol Cancer; 2012 May; 22(4):573-8. PubMed ID: 22398705
[TBL] [Abstract][Full Text] [Related]
9. Early-stage endometrioid ovarian carcinoma: population-based outcomes in British Columbia.
Kumar A; Le N; Tinker AV; Santos JL; Parsons C; Hoskins PJ
Int J Gynecol Cancer; 2014 Oct; 24(8):1401-5. PubMed ID: 25188885
[TBL] [Abstract][Full Text] [Related]
10. Is adjuvant radiotherapy in early stages (FIGO I-II) of epithelial ovarian cancer a treatment of the past?
Skirnisdottir I; Nordqvist S; Sorbe B
Oncol Rep; 2005 Aug; 14(2):521-9. PubMed ID: 16012740
[TBL] [Abstract][Full Text] [Related]
11. A risk-adapted strategy of adjuvant paclitaxel/carboplatin in early-stage ovarian cancer: time-dependent effect of 4 versus 6 cycles on outcome.
Bamias A; Bamia C; Karadimou A; Soupos N; Zagouri F; Rodolakis A; Haidopoulos D; Vlahos G; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2011; 81(5-6):365-71. PubMed ID: 22248920
[TBL] [Abstract][Full Text] [Related]
12. Survival impact of adjuvant paclitaxel and carboplatin for early-stage ovarian clear-cell carcinoma with complete surgical staging.
Kajiyama H; Shibata K; Suzuki S; Ino K; Kawai M; Nagasaka T; Nawa A; Kikkawa F
Gynecol Obstet Invest; 2011; 72(4):252-6. PubMed ID: 22041903
[TBL] [Abstract][Full Text] [Related]
13. Impact of adjuvant chemotherapy for stage I ovarian carcinoma with intraoperative tumor capsule rupture.
Shimizu D; Sato N; Sato T; Makino K; Kito M; Shirasawa H; Kumagai J; Terada Y
J Obstet Gynaecol Res; 2015 Mar; 41(3):432-9. PubMed ID: 25330897
[TBL] [Abstract][Full Text] [Related]
14. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary.
Nagai Y; Inamine M; Hirakawa M; Kamiyama K; Ogawa K; Toita T; Murayama S; Aoki Y
Gynecol Oncol; 2007 Dec; 107(3):469-73. PubMed ID: 17765295
[TBL] [Abstract][Full Text] [Related]
15. For women receiving chemotherapy for clinically apparent early ovarian cancer, is there a benefit to surgical staging?
Dizon DS; Restivo A; Lomme M; Charbonneau N; Brard L; Hughes T; Weitzen S; Legare R; Granai CO; Disilvestro P
Am J Clin Oncol; 2008 Feb; 31(1):39-42. PubMed ID: 18376226
[TBL] [Abstract][Full Text] [Related]
16. Impact of maintenance chemotherapy on disease-free survival in patients with stage Ic and II epithelial ovarian cancer.
Tanaka N; Matsui H; Nagai Y; Suzuka K; Seki K; Sekiya S
Eur J Gynaecol Oncol; 2002; 23(4):281-6. PubMed ID: 12214723
[TBL] [Abstract][Full Text] [Related]
17. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
Chan JK; Tian C; Fleming GF; Monk BJ; Herzog TJ; Kapp DS; Bell J
Gynecol Oncol; 2010 Mar; 116(3):301-6. PubMed ID: 19945740
[TBL] [Abstract][Full Text] [Related]
18. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
[TBL] [Abstract][Full Text] [Related]
19. The effect of adjuvant radiation on survival in early stage clear cell ovarian carcinoma.
Hogen L; Thomas G; Bernardini M; Bassiouny D; Brar H; Gien LT; Rosen B; Le L; Vicus D
Gynecol Oncol; 2016 Nov; 143(2):258-263. PubMed ID: 27623251
[TBL] [Abstract][Full Text] [Related]
20. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents.
Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA
Oncology; 2013; 84(3):158-65. PubMed ID: 23296063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
